Please login to view this media
- Talk
- 15/09/2021
- Canada
Variation in Operative and Non-Operative Treatment Rates for Paediatric Gartland Type II Supracondylar Humerus Fractures Across Multiple Canadian Centres
Description
This presentation is delivered by Sasha Carsen from CHEO University of Ottawa, representing the Canadian Type II Study Group, with Principal Investigator Dr. Chris Riley from BC Children's and UBC. The topic centers on a study investigating variability in treatment rates for pediatric Gartland's type II supracondylar humerus fractures at multiple Canadian hospitals. The research is motivated by existing controversies in treatment approaches for these common fractures, highlighting the examination of treatment patterns through prospective observational data.
The prospective multicenter observational trial involved patients aged 2 to 12 and aimed to assess operative vs. non-operative treatment rates while identifying variations across Canadian pediatric centers. The study included diverse sites, such as BC Children's Hospital and CHEO, and successfully recruited 309 patients, with most data collected now reflecting the study's goals effectively.
Key findings indicate significant treatment variability across the participating centers. Notably, two-thirds of patients underwent non-operative treatment, while one-third received operative treatment, with a notable portion of patients transitioning from non-operative to operative care. Data collection strategies involved detailing demographic, treatment method, and outcomes to analyze clinical and functional responses over time.
The study revealed varying treatment patterns based on center, and even within a single site, demonstrating a need for standardized treatment protocols and further evidence on clinical outcomes related to treatment types. The presentation concludes with a call for future research on the mid- to long-term patient outcomes to strengthen evidence on treatment efficacy.